Ursodeoxycholic acid (Ursofalk®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32016000671
English
Authors' recommendations:
Ursodeoxycholic acid (Ursofalk®) is recommended for use within NHS Wales for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2610
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Cholagogues and Choleretics
- Liver Cirrhosis, Biliary
- Ursodeoxycholic Acid
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.